163 related articles for article (PubMed ID: 9786256)
1. Activated protein C resistance in patients with peripheral vascular disease.
Sampram ES; Lindblad B; Dahlbäck B
J Vasc Surg; 1998 Oct; 28(4):624-9. PubMed ID: 9786256
[TBL] [Abstract][Full Text] [Related]
2. The impact of factor V mutation on the risk for occlusion in patients undergoing peripheral vascular reconstructions.
Sampram ES; Lindblad B
Eur J Vasc Endovasc Surg; 2001 Aug; 22(2):134-8. PubMed ID: 11472046
[TBL] [Abstract][Full Text] [Related]
3. Low prevalence of activated protein C resistance and coagulation factor V Arg506 to Gln mutation among Korean patients with deep vein thrombosis.
Kim TW; Kim WK; Lee JH; Kim SB; Kim SW; Suh C; Lee KH; Lee JS; Seo EJ; Chi HS; Kim SH
J Korean Med Sci; 1998 Dec; 13(6):587-90. PubMed ID: 9886165
[TBL] [Abstract][Full Text] [Related]
4. Factor V Leiden, activated protein C resistance, and retinal vein occlusion.
Ciardella AP; Yannuzzi LA; Freund KB; DiMichele D; Nejat M; De Rosa JT; Daly JR; Sisco L
Retina; 1998; 18(4):308-15. PubMed ID: 9730172
[TBL] [Abstract][Full Text] [Related]
5. Resistance to activated protein C due to factor V Leiden mutation: high prevalence in patients with post-thrombotic leg ulcers.
Gaber Y; Siemens HJ; Schmeller W
Br J Dermatol; 2001 Mar; 144(3):546-8. PubMed ID: 11260012
[TBL] [Abstract][Full Text] [Related]
6. Activated protein C resistance and factor V Leiden mutation can be associated with first-as well as second-trimester recurrent pregnancy loss.
Younis JS; Brenner B; Ohel G; Tal J; Lanir N; Ben-Ami M
Am J Reprod Immunol; 2000 Jan; 43(1):31-5. PubMed ID: 10698038
[TBL] [Abstract][Full Text] [Related]
7. Effect of exogenous estrogen on atherothrombotic vascular disease risk related to the presence or absence of the factor V Leiden mutation (resistance to activated protein C).
Glueck CJ; Wang P; Fontaine RN; Tracy T; Sieve-Smith L; Lang JE
Am J Cardiol; 1999 Sep; 84(5):549-54. PubMed ID: 10482153
[TBL] [Abstract][Full Text] [Related]
8. [Comparison of three reactants for the detection of activated protein C resistance due to mutation of factor V Leiden during pregnancy].
Magdelaine A; Soubrier F; Berkane N; Uzan S; Verdy E
Ann Biol Clin (Paris); 1998; 56(4):445-50. PubMed ID: 9754280
[TBL] [Abstract][Full Text] [Related]
9. Resistance to activated protein C (APC): mutation at Arg506 of coagulation factor V and vascular access thrombosis in haemodialysis patients.
Födinger M; Mannhalter C; Pabinger I; Koizar D; Rintelen C; Hörl WH; Sunder-Plassmann G
Nephrol Dial Transplant; 1996 Apr; 11(4):668-72. PubMed ID: 8671856
[TBL] [Abstract][Full Text] [Related]
10. Determination of activated protein C resistance in anticoagulated and lupus positive patients.
Ivey LM; Thom JY; Ivey JG; Baker RI
Blood Coagul Fibrinolysis; 2000 Jul; 11(5):439-45. PubMed ID: 10937805
[TBL] [Abstract][Full Text] [Related]
11. Activated protein C resistance and the FV:R506Q mutation in a random population sample--associations with cardiovascular risk factors and coagulation variables.
Lowe GD; Rumley A; Woodward M; Reid E; Rumley J
Thromb Haemost; 1999 Jun; 81(6):918-24. PubMed ID: 10404768
[TBL] [Abstract][Full Text] [Related]
12. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism.
Rodeghiero F; Tosetto A
Ann Intern Med; 1999 Apr; 130(8):643-50. PubMed ID: 10215560
[TBL] [Abstract][Full Text] [Related]
13. Resistance to activated protein C, factor V leiden and the prothrombin G20210A variant in patients with colorectal cancer.
Paspatis GA; Sfyridaki A; Papanikolaou N; Triantafyllou K; Livadiotaki A; Kapsoritakis A; Lydataki N
Pathophysiol Haemost Thromb; 2002; 32(1):2-7. PubMed ID: 12214157
[TBL] [Abstract][Full Text] [Related]
14. Modification of the ProC Global assay using dilution of patient plasma in factor V-depleted plasma as a screening assay for factor V Leiden mutation.
Quincampoix JC; Legarff M; Rittling C; Andiva S; Toulon P
Blood Coagul Fibrinolysis; 2001 Oct; 12(7):569-76. PubMed ID: 11685046
[TBL] [Abstract][Full Text] [Related]
15. Detection of factor V Leiden in Thai patients with venous thrombosis.
Prayoonwiwat W; Arnutti P; Hiyoshi M; Nathalang O; Suwanasophon C; Kokaseam R; Krutvecho T; Tatsumi N
Asian Pac J Allergy Immunol; 2000 Jun; 18(2):105-8. PubMed ID: 10928623
[TBL] [Abstract][Full Text] [Related]
16. Activated protein C resistance in anterior ischaemic optic neuropathy.
Nagy V; Facsko A; Takacs L; Balazs E; Berta A; Balogh I; Edes I; Czuriga I; Pfliegler G
Acta Ophthalmol Scand; 2004 Apr; 82(2):140-3. PubMed ID: 15043529
[TBL] [Abstract][Full Text] [Related]
17. [Activated protein C resistance, Leiden mutation, anticoagulant proteins and fibrinogen levels in patients with deep venous thrombosis].
Jastrzebska M; Bałszan-Kowalska I; Ciechanowicz A; Bińczak-Kuleta A; Falkowski A; Chełstowski K
Pol Arch Med Wewn; 2003 Jun; 109(6):579-88. PubMed ID: 14567090
[TBL] [Abstract][Full Text] [Related]
18. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis.
de Visser MC; Rosendaal FR; Bertina RM
Blood; 1999 Feb; 93(4):1271-6. PubMed ID: 9949170
[TBL] [Abstract][Full Text] [Related]
19. [Increased prevalence of APC-resistance (factor V Leiden mutation) in patients with postthrombotic syndrome].
Gaber Y; Siemens HJ; Schmeller W
Hautarzt; 2000 Aug; 51(8):590-2. PubMed ID: 10997314
[TBL] [Abstract][Full Text] [Related]
20. The clinical application of a new specific functional assay to detect the factor V(Leiden) mutation associated with activated protein C resistance.
van Oerle R; van Pampus L; Tans G; Rosing J; Hamulyák K
Am J Clin Pathol; 1997 May; 107(5):521-6. PubMed ID: 9128263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
